Pulmagen Therapeutics (Inflammation) Limited

Craig Fox

Harry Finch

Mohammed Sajad

Andrew Forrest

Monique Bondil Van Niel

Monique Bodil Van Niel

Vidya Ramdas

A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.

Respiratory disease treatment

There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.

Compounds of formula (I) are agonists of PPAR&#x3b3;, useful for the treatment of respiratory disease; formula (I): wherein R, Ror Reach independently represents halo, cyano, nitro, amino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxylic acid or an ester or amide thereof; Rrepresents hydrogen or alkyl; m, n or p independently represents 0, 1, 2 or 3. 

Growing community of inventors

Buckinghamshire, United Kingdom

Craig Fox